Motilal Oswal Recommends Buy on Glenmark Pharma with Rs 2,610 Target Price
Motilal Oswal's research report on Glenmark Pharma noted a mixed quarterly performance with revenue meeting estimates but EBITDA falling 7% short. Higher other income led to a 9% beat on profit after tax. Domestic formulation and US segments underperformed, partly due to Middle East logistics disruptions, while Europe and other regions exceeded expectations. The firm anticipates US revenue growth to improve by FY27, supported by niche product approvals, and has raised earnings estimates for FY27 and FY28, assigning a target price of Rs 2,610 based on 25x forward earnings.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 100%, Right 0%). Overall sentiment is neutral (65/100). Lens Score 24/100 — low public interest.
Outlets analysed (first-hand measurement by TBN's Bias Engine):
- moneycontrol— balanced framing, neutral sentiment
- moneycontrol— balanced framing, neutral sentiment
- moneycontrol— balanced framing, neutral sentiment
AI Analysis
The article group presents a financial analysis from a brokerage firm without political framing. It focuses on company performance, market expectations, and investment recommendations, reflecting a business and investment perspective. There is no evident political viewpoint or ideological bias in the coverage.
The overall tone is cautiously optimistic, balancing acknowledgment of recent underperformance with positive outlooks for future growth and earnings upgrades. The sentiment is primarily neutral to mildly positive, emphasizing factual financial data and forward-looking projections without emotional language.
How 3 sources covered this story
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.